FibroBiologics Files Patent for Innovative Approach to Enhance Mitochondrial Performance Using Fibroblasts

FibroBiologics, Inc. a clinical-stage biotechnology company with over 160 issued and pending patents focused on the development of therapeutics and potenti...

March 05, 2025 | Wednesday | News
Myosin Therapeutics Secures Funding to Advance MT-125 for Glioblastoma, MT-110 for Addiction

 Myosin Therapeutics, Inc., a biotechnology company developing novel therapies for cancer and neurological disorders, has closed its second seed fundi...

March 04, 2025 | Tuesday | News
CStone Begins Phase I Trial of CS2009 Trispecific Antibody for Solid Tumors

CStone Pharmaceuticals, an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, announced that&nbs...

March 04, 2025 | Tuesday | News
Avecho Biotechnology Partners with Sandoz for Exclusive Australian Rights to CBD Insomnia Capsule

Avecho Biotechnology Limited  announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG ("Sandoz") for th...

March 04, 2025 | Tuesday | News
Celldex Reports Positive Phase 2 Results for Barzolvolimab in Chronic Urticaria

Celldex Therapeutics, Inc. announced  positive data on measurements of disease control and quality of life from the Company’s Phase 2 barzolvoli...

March 03, 2025 | Monday | News
Jasper Therapeutics Presents Promising Updated Data on Briquilimab for Mast Cell-Driven Diseases at AAAAI 2025

Jasper Therapeutics, Inc. (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit ...

March 03, 2025 | Monday | News
GSK Announces Positive Phase III Results for Depemokimab in Treating Chronic Rhinosinusitis with Nasal Polyps

GSK plc announced full results from the positive ANCHOR-1 and ANCHOR-2 phase III clinical trials assessing the efficacy and safety of depemokimab versus pl...

March 03, 2025 | Monday | News
Amgen and AstraZeneca's TEZSPIRE® Demonstrates Significant Efficacy in Phase 3 WAYPOINT Trial for Chronic Rhinosinusitis with Nasal Polyps

Amgen and AstraZeneca announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE® (tezepelumab-ekko) signi...

March 03, 2025 | Monday | News
Roche Group Unveils Promising Results from NIH-Sponsored OUtMATCH Study, Highlighting Xolair® as a Leading Treatment for Food Allergies

Roche Group announced new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored Phase III OUtMATCH study, which provi...

March 03, 2025 | Monday | News
CARsgen Therapeutics Initiates First Patient Dosing of KJ-C2219 in Systemic Lupus Erythematosus Trial

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors,...

February 28, 2025 | Friday | News
Alumis to Present Data on A-005, a Novel TYK2 Inhibitor, at ACTRIMS Forum 2025

Alumis Inc. (“Alumis” or the “Company”), a clinical stage biopharmaceutical company developing oral therapies using a precision app...

February 28, 2025 | Friday | News
Nxera Pharma Signs Agreement with Viatris and Idorsia for Cenerimod Development and Commercialization in Japan, South Korea, and APAC

Nxera Pharma has entered an assignment agreement with Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Pharmaceuticals Ltd (&...

February 28, 2025 | Friday | News
Medigene and EpimAb Partner to Advance Off-the-Shelf TCR-TCE Therapies for Cancer

Medigene AG and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and dev...

February 27, 2025 | Thursday | News
Avance Biosciences Earns CLIA Registration to Enhance Clinical Trial Support

Avance Biosciences, a leading provider of high-quality analytical and bioanalytical services for the pharmaceutical industry, is pleased to announce that i...

February 27, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close